Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
The CSB Trial Team

You are here:

CSB Trial Team

The Trial Team at the Center for Stroke Research Berlin optimizes clinical study conditions. Its goal is to relieve scientists and to professionalize investigator-initiated trials, i.e., studies initiated by researchers at academic institutions, not by the pharmaceutical industry. The initiator of a study has one central contact person for all aspects of their study, and this person organizes and carries out all necessary tasks with the help of the Trial Team.

The Trial Team works on all three campuses: Campus Benjamin Franklin, Campus Charité Mitte and Campus Virchow-Klinikum. This means that team members, especially study doctors, will rotate around the campuses in the coming years. The physicians are integrated in the medical curriculum of the Department of Neurology and Experimental Neurology.

Head of Trial Team

Prof. Christian Nolte, MD

Head of CSB Trial Team, Head of Research Group Nolte (Heart-Brain Interaction)

CBF: Campus Benjamin Franklin

Prof. Christian Nolte, MD

Contact Trial Team

The trial team has a trial service center at Campus Mitte, Campus Virchow, and Campus Benjamin Franklin as well as a centrally organized emergency service.
The trial service will be notified by the clinic physicians whenever a patient presents with acute cerebral ischemia, intracerebral or subarachnoidal hemorrhage.

Study physician phone no.: +49 172 150 82 98

Our patient phone can be reached on weekdays from 9 a.m. to 3 p.m. by calling +49 30 450 560 698.

Facts and Figures

Each year, at the three stroke units of the Department of Neurology and Experimental Neurology at Charité – Universitätsmedizin Berlin – i.e. Campus Benjamin Franklin, Campus Charité Mitte and Campus Virchow-Klinikum – approximately 2400 stroke patients are treated.
The Trial Team and its partners conduct a multitude of stroke trials. Since 2009, more than 9200 patients (status January 2022) have taken part in at least one clinical observation or interventional trial.